Regulus Therapeutics Inc

NASDAQ RGLS

Data sourced from

and

Download Data

Regulus Therapeutics Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2024: USD -841.00 K

Regulus Therapeutics Inc Capital Expenditures is USD -841.00 K for the Trailing 12 Months (TTM) ending March 31, 2024, a -223.46% change year over year. Capital Expenditures represent the amount of money spent on acquiring or improving long-term assets, such as property, plant, and equipment.

Regulus Therapeutics Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -260.00 K, a 13.33% change year over year.
Regulus Therapeutics Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -300.00 K, a 24.24% change year over year.
Regulus Therapeutics Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -396.00 K, a -31.56% change year over year.
Regulus Therapeutics Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -301.00 K, a 51.99% change year over year.

NASDAQ: RGLS

Regulus Therapeutics Inc

CEO	Mr. Joseph P. Hagan M.B.A.
IPO Date	Oct. 4, 2012
Location	United States
Headquarters	4224 Campus Point Court, San Diego, CA, United States, 92121
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key trends